rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IBIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline
      Nov 12Yahoo FinanceIBIO
      Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor
      Oct 29BenzingaIBIO
      iBio Shareholders Approve Governance and Capital Structure Changes

      Detailed price information for Ibio Inc (IBIO-Q) from The Globe and Mail including charting and trades.

      Oct 20The Globe and MailIBIO
      iBio reports muscle preservation data for obesity drug candidate
      Oct 13Investing.comIBIO
      iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow (NASDAQ:IBIO) 2026-10-07

      2026-10-07. The following slide deck was published by iBio, Inc.

      Oct 7Seeking AlphaIBIO
      iBio stock initiated at buy by H.C. Wainwright with $7 target
      Sep 17Investing.comIBIO
      This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
      Sep 17BenzingaPAYIBIO
      This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursda
      Sep 17BenzingaIBIO
      12 Health Care Stocks Moving In Monday's After-Market Session - Circle8 Group (NASDAQ:CIRC), Eocene (NASD

      Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose 10.65% to

      Sep 14BenzingaBDMDIBIO
      iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
      Sep 1Yahoo FinanceWFCIBIO
      iBio reports $33 million loss for fiscal 2026, advances pipeline
      Aug 28Investing.comIBIO
      iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

      SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase

      Aug 28Yahoo FinanceIBIO

      This is the newest page. Registered accounts read further back.